Strategic framework for education and training in Quality by Design (QbD) and process analytical technology (PAT)

Advancement of Emerging Technology Applications to Modernize the Pharmaceutical Manufacturing Base – guidance for industry - draft guidance – US FDA 2015 Aksu, 2012, Strategic funding priorities in the pharmaceutical sciences allied to quality by design (QbD) and process analytical technology (PAT)), Eur. J. Pharm. Sci., 47, 402, 10.1016/j.ejps.2012.06.009 Atkinson, 2012, Survey of pharmaceutical education in Europe, Pharmine – report on the integration of the industry component in pharmacy education and training, Eur. Ind. Pharm., 1, 3 Bridging the skills gaps in the biopharmaceutical industry – Maintaining the UK's leading position in life sciences, ABPI, December 2015. (http://www.abpi.org.uk/industryinfo/education/Documents/Skills_Gap_Industry_No_Appendices.pdf.) Crommelin, 2010, Pharmaceutical sciences in 2020, Nat. Rev. Drug Discov., 9, 99, 10.1038/nrd3087 Final deliverable for FDA Understanding Challenges to QbD Project, December 18, 2009. ICH Harmonised Tripartite Guideline Q10 – Pharmaceutical Quality System. ICH Guidance for Industry, June 2008. <http://www.ich.org>. ICH Harmonised Tripartite Guideline Q11 - Development and Manufacture of Drug Substances (chemical entities and biotechnological/biological entities), May 2012. ICH Final Concept Paper Q12 – Technical and regulatory considerations for pharmaceutical product lifecycle management, September 2014. ICH Harmoised Tripartite Guideline Q8(R2) – Pharmaceutical Development. ICH Guidance for Industry, August 2009. ICH Harmonised Tripartite Guideline Q9 – Quality Risk Management. ICH Guidance for Industry, November 2005. Kourti, 2012, The business benefits of quality by design, Pharm. Eng., 32, 1 Menezes, 2010, Pharmaceutical engineering: the Lisbon masters program Moore, 2013, A regulatory perspective on the current and future state of pharmaceutical quality Pharmaceutical cGMPs for the 21st century – A risk based approach – Final Report, US FDA 2004. Rantanen, 2015, The future of pharmaceutical manufacturing sciences, J. Pharm. Sci., 104, 3612, 10.1002/jps.24594 Selen, 2014, The biopharmaceutics risk assessment roadmap for optimizing clinical drug product performance, J. Pharm. Sci., 103, 3377, 10.1002/jps.24162